Metropolitan Life Insurance Company (MetLife)’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,785	Closed	-$11.2K	–	2535
2023 Q1	$11.2K	Sell	1,785 -223	-11%	-$1.36K	﹤0.01%	2117
2022 Q4	$12.2K	Buy	2,008 +156	+8%	+$1.27K	﹤0.01%	2217
2022 Q3	$22.1K	Hold	1,852	–	–	﹤0.01%	1981
2022 Q2	$23.4K	Hold	1,852	–	–	﹤0.01%	1968
2022 Q1	$20.9K	Sell	1,852 -5,658	-75%	-$62.3K	﹤0.01%	2073
2021 Q4	$133K	Hold	7,510	–	–	﹤0.01%	2299
2021 Q3	$173K	Buy	+7,510	New	+$163K	﹤0.01%	2187
2021 Q2	–	Sell	-4,693	Closed	-$146K	–	2908
2021 Q1	$146K	Buy	+4,693	New	+$164K	﹤0.01%	2226

Other funds holding KNTE

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $508M AUM 163.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s KNTE Position: Q2 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2023, closing a stake of 1,785 shares — an estimated $11.2K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in KNTE in Q1 2021 and held it in 8 quarters. The position peaked at $173K in Q3 2021. 72 funds tracked by Wall St. Rank hold KNTE as of Q2 2023.

Metropolitan Life Insurance Company (MetLife) reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,785 Kinnate Biopharma Inc. Common Stock shares in Q2 2023, an estimated $11.2K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2021 and held it in 8 quarters.
Metropolitan Life Insurance Company (MetLife)'s Kinnate Biopharma Inc. Common Stock position peaked at $173K in Q3 2021.
72 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2023, filed 10 Aug 2023.